JAGSNPHARM Share Price Target 2035
CAGR-based price projection for Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) targeting 2035, derived from official NSE exchange closing prices.
Current Market Snapshot
Year-by-Year Price Projection
| Year | Bear Case | Base Case | Bull Case |
|---|---|---|---|
| 2027 | Rs 250 | Rs 278 | Rs 365 |
| 2028 | Rs 271 | Rs 334 | Rs 575 |
| 2029 | Rs 292 | Rs 402 | Rs 906 |
| 2030 | Rs 316 | Rs 482 | Rs 1,428 |
| 2031 | Rs 341 | Rs 579 | Rs 2,249 |
| 2032 | Rs 369 | Rs 696 | Rs 3,543 |
| 2033 | Rs 398 | Rs 836 | Rs 5,583 |
| 2034 | Rs 430 | Rs 1,004 | Rs 8,795 |
| 2035 | Rs 465 | Rs 1,206 | Rs 13,857 |
Frequently Asked Questions
What is the JAGSNPHARM share price target for 2035?
Based on historical growth analysis, the JAGSNPHARM share price target for 2035 ranges from Rs 465 (conservative) to Rs 1,206 (base case) to Rs 13,857 (optimistic). These projections are based on trailing CAGR and should not be treated as guaranteed outcomes.
What is the current share price of JAGSNPHARM?
The current market price of JAGSNPHARM (Jagsonpal Pharmaceuticals Limited) is Rs 231.73. The 52-week high is Rs 243.97 and 52-week low is Rs 185.42.
Is JAGSNPHARM a good stock to buy for the long term?
Long-term investment decisions depend on individual risk tolerance, financial goals, and portfolio diversification. Examine the company's fundamentals, debt-to-equity ratio, promoter holding, and competitive positioning within its sector. BrokerLens provides data-driven analysis; consult a SEBI-registered financial advisor before investing.
What methodology does BrokerLens use for JAGSNPHARM price targets?
BrokerLens computes price targets using historical Compound Annual Growth Rate (CAGR) derived from official NSE closing prices. Three scenarios are modeled: Bear (conservative at 8.0% CAGR), Base (20.1% CAGR), and Bull (optimistic at 57.5% CAGR). These are statistical projections, not guaranteed forecasts.